drugset / Trial / NCT00226408

Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

NCT00226408

Phase 3 Unknown 600 enrolled Dermatologic Cooperative Oncology Group
RandomizedParallel-groupOpen-labelTreatment

Summary

The study protocol is being conducted to compare intermittent high-dose i.v. administation of interferon alpha-2b with the standard high-dose treatment by Kirkwood with distant metastasis free survival (DMFI) as a primary endpoint.

Timeline

Start
2003-11
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject interferon alfa-2b Protein / enzyme biologic 10 unknown Intravenous
Subject interferon alfa-2b Protein / enzyme biologic 20 unknown Intravenous

Indications